Phenomics in Autoimmune and Inflammatory Diseases

Rheumatoid Arthritis Clinical Trial

— TRANSIMMUNOM  

Official title:

Clinical and Multi-omics Cross-phenotyping of Patients With Autoimmune and Auto-inflammatory Diseases

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02466217
• Other study ID #: P141006
• Secondary ID: 2015-A00558-41
• Status: Completed
• Start date: July 29, 2015
• Est. completion date: July 18, 2022

Study information

• Verified date: August 2023
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The family of inflammatory/autoimmune systemic diseases (IAD) form a continuum from pure inflammatory diseases to pure autoimmune diseases, encompassing a large panel of inflammatory diseases with some autoimmune components, and vice versa. Cross phenotyping of patients with IAD should be heuristic and help revise the nosography and the understanding of these diseases.

Description:

The family of inflammatory/autoimmune systemic diseases (IAD) represents a large group of human diseases. For most if not all of these IAD, the pathophysiological processes or exact causes remain poorly understood. Progresses in molecular understanding of these IAD have led to realize that these are not two distinct categories of diseases. Rather they form a continuum from pure inflammatory diseases to pure autoimmune diseases, encompassing a large panel of inflammatory diseases with some autoimmune components, and vice versa.

Using systems biology, the investigator aims to improve the understanding of these diseases, to identify novel genes/pathways involved, specific or across the diseases, and to discover biomarkers and potential therapeutic targets.

The investigator will study adult patients with at least one of the following IAD: Rheumatoid Arthritis, Ankylosing Spondylitis, Systemic Lupus Erythematosus/Antiphospholipid Syndrome, Familial Mediterranean Fever (FMF), Cryopyrin-Associated Periodic Syndromes (CAPS) /Tumor Necrosis Factor-receptor Associated Periodic Syndrome (TRAPS), Vasculitis, Uveitis, Myositis, Crohn's Disease, Ulcerative colitis, Type 1 Diabetes. This panel will be completed by controls groups: healthy volunteers, and patients with arthritis (knee and/or hip) or muscular dystrophy.

The biological investigations will notably comprise: immunomics (comprehensive evaluation of peripheral blood cell subsets and serum immunoproteomics, including autoantibodies); transcriptomics; Human Leukocyte Antigen (HLA)-phenotyping; genomics; T-Cell Receptor (TCR) sequencing and microbiota studies.

After signing the informed consent, the subject attends only one visit (Day 0) during which all biological samples will be taken and all clinical information collected.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 537
• Est. completion date: July 18, 2022
• Est. primary completion date: July 14, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Presenting either:

• one IAD from our list (Rheumatoid Arthritis, Ankylosing Spondylitis, Systemic Lupus Erythematosus/Antiphospholipid Syndrome, FMF, Cryopyrin-Associated Periodic Syndromes (CAPS)/Tumor Necrosis Factor (TNF)-receptor Associated Periodic Syndrome, Vasculitis, Uveitis, Myositis, Crohn's Disease, Ulcerative colitis, Type 1 Diabetes)

• or an unclassified IAD : a knee and/or hip arthritis or a muscular dystrophy

• or healthy subject

• Good veins

• Affiliation to a social security system

• Informed consent form, signed by the participant and the investigator, prior all needed examination

Exclusion Criteria:

• For IADs patients

• Unauthorized treatment (anticancer chemotherapy)

• For Healthy volunteers

• Contra-indications for donating blood except from age

• Known history of IAD (eg: Psoriasis)

• Common exclusion criteria:

• Pregnant woman

• Still under the exclusion period from another biomedical study

• Psychiatric or addiction pathology who could interfere with the ability to fulfill the protocol needs or to provide an informed consent

• Patient under a legal protection

• Chronic lifelong viral infection unrelated to the pathology

• Mild infection within the last 3 months

Related Conditions & MeSH terms

• Ankylosing Spondylitis
• Antiphospholipid Syndrome
• Arthritis
• Crohn Disease
• Crohn's Disease
• Cryopyrin-Associated Periodic Syndromes
• Cryopyrin-Associated Periodic Syndromes /TNF-receptor Associated Periodic Syndrome
• FMF
• Healthy Volunteer
• Lupus Erythematosus, Systemic
• Muscular Dystrophies
• Myositis
• Proctocolitis
• Rheumatoid Arthritis
• Spondylitis
• Spondylitis, Ankylosing
• Syndrome
• Systemic Lupus Erythematosus/Antiphospholipid Syndrome
• Type 1 Diabetes
• Ulcerative Rectocolitis
• Unclassified IAD Knee and/or Hip Arthritis, Muscular Dystrophy
• Uveitis
• Vasculitis

Intervention

Other:
• 1: AID groups
Clinical and Biological investigations
• 2: Control groups
Clinical and Biological investigations

Locations

Country	Name	City	State
France	CIC Paris-Est, Hôpital PITIE SALPETRIERE	Paris
France	Rhumatologie - Hôpital Saint-Antoine	Paris

Sponsors (2)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris	National Research Agency, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total peripheral blood gene expression between patients, expressed as fluorescence intensity	Identification of novel molecular and cellular pathways involved either in specific diseases or across the IAD continuum through a multiparametric approach	at day 0, no follow-up
Primary	Tregs and Tconvs T cell receptor repertoire, expressed as the % of unique TCR sequences	Identification of novel molecular and cellular pathways involved either in specific diseases or across the IAD continuum through a multiparametric approach	at day 0, no follow-up
Primary	HLA type and SNPs expressed as the occurrence events across patients	Identification of novel molecular and cellular pathways involved either in specific diseases or across the IAD continuum through a multiparametric approach	at day 0, no follow-up
Primary	Microbiote species identification expressed as the % of species per family and genus	Identification of novel molecular and cellular pathways involved either in specific diseases or across the IAD continuum through a multiparametric approach	at day 0, no follow-up
Primary	Cytokines and chemokines expressed as fluorescence intensity	Identification of novel molecular and cellular pathways involved either in specific diseases or across the IAD continuum through a multiparametric approach	at day 0, no follow-up
Primary	Immune cells phenotyping expressed as the each cell type % within total PBMCs	Identification of novel molecular and cellular pathways involved either in specific diseases or across the IAD continuum through a multiparametric approach	at day 0, no follow-up
Secondary	Changes in gene expression intensity between patients and healthy controls - for each Disease cohorts	Identification of new biomarkers and potential therapeutic by multiscale analysis	at day 0, no follow-up
Secondary	Changes in Tregs and Tconvs TCR sequence frequencies between patients and healthy controls - for each Disease cohorts	Identification of new biomarkers and potential therapeutic by multiscale analysis	at day 0, no follow-up
Secondary	Characterization of HLA and SNP profiles in patients and healthy controls - for each Disease cohorts	Identification of new biomarkers and potential therapeutic by multiscale analysis	at day 0, no follow-up
Secondary	Changes in Microbiote composition between patients and healthy controls - for each Disease cohorts	Identification of new biomarkers and potential therapeutic by multiscale analysis	at day 0, no follow-up
Secondary	Changes in cytokines and chemokines expression levels between patients and healthy controls - for each Disease cohorts	Identification of new biomarkers and potential therapeutic by multiscale analysis	at day 0, no follow-up
Secondary	Changes in immune cells frequencies between patients and healthy controls - for each Disease cohorts	Identification of new biomarkers and potential therapeutic by multiscale analysis	at day 0, no follow-up
Secondary	Identification of specific and common gene expression levels between patients - between Disease cohorts	Identification of new biomarkers and potential therapeutic by multiscale analysis	at day 0, no follow-up
Secondary	Identification of specific and common Tregs and Tconvs TCR sequence frequencies between patients - between Disease cohorts	Identification of new biomarkers and potential therapeutic by multiscale analysis	at day 0, no follow-up
Secondary	Characterization of specific and common HLA and SNP profiles in patients - between Disease cohorts	Identification of new biomarkers and potential therapeutic by multiscale analysis	at day 0, no follow-up
Secondary	Identification of specific and common microbiote composition between patients - between Disease cohorts	Identification of new biomarkers and potential therapeutic by multiscale analysis	at day 0, no follow-up
Secondary	Identification of specific and common cytokines and chemokines expression levels between patients - between Disease cohorts	Identification of new biomarkers and potential therapeutic by multiscale analysis	at day 0, no follow-up
Secondary	Characterization specific and common variations in immune cells frequencies between patients - between Disease cohorts	Identification of new biomarkers and potential therapeutic by multiscale analysis	at day 0, no follow-up